PWAM
PGNX

Park West Asset Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Park West Asset Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-907,351
Closed -$6.16M – 85
2017
Q2 		$6.16M Sell
907,351
-1,586,745
-64% -$11.7M 0.34% 53
2017
Q1 		$23.5M Buy
2,494,096
+1,259,910
+102% +$12.6M 1.37% 28
2016
Q4 		$10.7M Buy
1,234,186
+690,426
+127% +$5.1M 0.82% 36
2016
Q3 		$3.44M Buy
+543,760
New +$3.29M 0.31% 46

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

Park West Asset Management's PGNX Position: Q3 2017 in Review

Park West Asset Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2017, closing a stake of 907,351 shares — an estimated $6.16M sold.

Park West Asset Management first reported a position in PGNX in Q3 2016 and held it in 4 quarters. The position peaked at $23.5M in Q1 2017. 142 funds tracked by Wall St. Rank hold PGNX as of Q3 2017.

  • Park West Asset Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Park West Asset Management sold 907,351 Progenics Pharmaceuticals Inc shares in Q3 2017, an estimated $6.16M.
  • Park West Asset Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 4 quarters.
  • Park West Asset Management's Progenics Pharmaceuticals Inc position peaked at $23.5M in Q1 2017.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2017.

Based on Park West Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.